Japan Ministry of Health, Labor and Welfare Approves Manufacturing and Marketing of Adtralza® (tralokinumab) in Japan for Adults with Atopic Dermatitis
“Today’s approval is a significant advancement for those patients in Japan who continue to suffer from the often-debilitating symptoms of atopic dermatitis and are in need of a new treatment option to manage their chronic condition,” said Kook Hyun Son, General Manager of LEO Pharma K.K. “We have made substantial investments in our infrastructure, including the hiring of dedicated medical staff to ensure dermatologists receive the latest Adtralza clinical information to help inform treatment decisions for their patients.”
Adtralza is the first and only approved human, monoclonal antibody developed to specifically target and neutralize the IL-13 cytokine, which plays a key role in the immune and inflammatory process which are the underlying causes of atopic dermatitis signs and symptoms.1,2 The MHLW has approved Adtralza to be administered as a subcutaneous injection in adults with an initial dose of 600mg, followed by a 300mg dose given every other week.
“The Japan approval is a demonstration of our strategy to expand the availability of Adtralza to millions of patients around the world who are faced with the daily challenges of living with chronic and often debilitating symptoms of atopic dermatitis,” said Becki Morison, executive vice president of global strategy and international operations, LEO Pharma A/S. “We continue to evaluate regulatory filings in markets where there is the greatest need to help ensure patients who may benefit from Adtralza will have access to this biologic therapy.”
About the ECZTRA 8 trial
ECZTRA 8 was a 16-week, double-blind, randomized, placebo-controlled phase 3 study in Japanese patients. The study evaluated the efficacy and safety of tralokinumab (300 mg) in combination with TCS in 106 adult patients with atopic dermatitis who were candidates for systemic therapy having an inadequate response to existing therapy.5
About the ECZTEND - long-term extension (LTE) trial
ECZTEND (Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous tralokinumab Trials) is an ongoing Phase 3, long-term five-year, open-label, single-arm
extension trial to evaluate the efficacy and safety of tralokinumab in patients with atopic dermatitis who participated in the previous tralokinumab monotherapy trials (ECZTRA 1 and ECZTRA 2), the combination therapy tralokinumab plus TCS trial (ECZTRA 3), the Drug-drug interaction (DDI) trial (ECZTRA 4), the vaccine trial (ECZTRA 5), the adolescent trial (ECZTRA 6), the oral cyclosporine A trial (ECZTRA 7), the combination therapy tralokinumab plus TCS trial in Japanese subjects (ECZTRA 8), and the tralokinumab monotherapy skin barrier function trial (TraSki). Patients were permitted to enter ECZTEND after completion of the parent trial regardless of their treatment response or whether they were treated with tralokinumab or placebo.6,7
About atopic dermatitis
Atopic dermatitis is a chronic, inflammatory, skin disease characterized by intense itch and eczematous lesions.8 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.9 Type 2 cytokines, including IL-13, play a central role in the key aspects of atopic dermatitis pathophysiology.2
About Adtralza® (tralokinumab)
Tralokinumab is a human monoclonal antibody developed to specifically neutralize the IL-13 cytokine. Tralokinumab specifically binds to the IL-13 cytokine with high affinity, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).1,2
Adtralza® / Adbry™ (tralokinumab-ldrm) is approved for the treatment of adults with moderate-to-severe AD in the European Union, United States, Great Britain, Canada, the United Arab Emirates, and Switzerland.
- Popovic B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017; 429:208–19.
- Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54–62.
- Wollenberg A, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021; 437-449.
- Silverberg JI, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021; 450-463.
- ClinicalTrials.gov Identifier: NCT04587453
- Blauvelt et. al. Two-year Maintenance of Response with Tralokinumab in Moderate-to-Severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial. European Academy of Dermatology and Venereology (EADV). Sept 29-Oct 2, 2021. On-demand video oral presentation FC01.04.
- EU Clinical Trials Register. Long-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTEND. EudraCT number: 2018-000746-19. https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000746-19/GB.
- Weidinger S, et al. Atopic dermatitis. Lancet. 2016; 387:1109-1122.
- Boguniewicz M, et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233-46
LEO Pharma A/S Global Media Contact:
+45 3140 6180
LEO Pharma K.K. Japan Media contact:
About LEO Pharma
About LEO Pharma A/S
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,200 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
About LEO Pharma K.K. (Japan)
LEO Pharma K.K. was established in June 2010 as a wholly owned Japanese corporation of LEO Pharma A/S in Denmark. LEO Pharma K.K. is conducting business activities to establish a solid position in Japan as a specialty pharmaceutical company specializing in dermatology. For more information, please visit http://www.leo-pharma.jp/.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma presents late-breaking positive Phase 2a efficacy and safety results of LEO 138559 in moderate-to-severe atopic dermatitis at the 2023 AAD Annual Meeting18.3.2023 21:10:00 CET | Press release
• Results presented at AAD 2023 demonstrated that investigational agent LEO 138559 met its primary endpoint of change in the Eczema Area and Severity Index (EASI) compared with placebo1 • Efficacy analysis showed significant improvement versus placebo across a variety of endpoints including EASI-75, EASI-90, and EASI-100, in adult patients with moderate-to-severe atopic dermatitis1 • These results are the first to be presented for an IL-22 receptor targeting antibody for the treatment of moderate-to-severe atopic dermatitis1
LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 202318.3.2023 17:40:00 CET | Press release
• Results demonstrated that delgocitinib cream provided statistically significant improvements in primary and all key secondary endpoints, which included both clinician-assessed and patient-reported efficacy outcomes compared to cream vehicle.1 • Delgocitinib cream showed a statistically significant treatment effect compared to cream vehicle as early as four weeks after initiation of treatment.1
LEO Pharma Presents New Adbry™ (tralokinumab-ldrm) Data in Adolescent Population from ECZTRA 6 and ECZTEND Trials at AAD 2023 Annual Meeting17.3.2023 13:00:00 CET | Press release
• Analysis from the ECZTRA 6 trial shows positive effects of Adbry on reducing Staphylococcus aureus skin colonization that contributes to skin irritation and infections, and improving gene expression toward a non-lesional skin profile in adolescents with moderate-to-severe atopic dermatitis (AD).1,2 • Interim analysis of adolescent patients in the ECZTEND trial demonstrates that long-term use of Adbry for up to three years had a similar safety profile to the adult population, and approximately eight out of 10 patients had at least a 75% improvement in the extent and severity of their AD (EASI-75) at two years.3
LEO Pharma adds internationally recognized dermatologist to Global Leadership Team14.3.2023 14:00:00 CET | Press release
Ballerup, March 14, 2023 – LEO Pharma today announced a split of its R&D organization into two distinct functions. To lead Research and Early Development, LEO Pharma has appointed Dr. Jacob Pontoppidan Thyssen as new Executive Vice President and Chief Scientific Officer. Jacob is an internationally recognized dermatologist and key opinion leader who will add his clinical experience and strong understanding of patients’ needs into LEO Pharma’s drug development.
LEO Pharma and ICON enter a Strategic Partnership to propel clinical trial execution within medical dermatology10.3.2023 08:00:00 CET | Press release
BALLERUP, DENMARK and DUBLIN, IRELAND — March 10, 2023 — LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organizations in the industry.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom